Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Outlook Therapeutics announced FDA approval of LYTENAVA™ (bevacizumab-vikg), the first ophthalmic bevacizumab specifically developed for intravitreal administration to treat neovascular (wet) age-related macular degeneration (AMD). This approval grants the company 12 years of market exclusivity and positions LYTENAVA as a new standard in retina car…